What is this medicine used for?
FDA-approved uses
- Attention-deficit/hyperactivity disorder (ADHD) — Adults and pediatric patients aged 6 years and older weighing at least 20 kg. Once-daily treatment for ADHD within the labeled age and weight boundaries.Simtriyo extended-release oral capsules.
What should I expect?
Take Simtriyo once each morning exactly as prescribed. Track ADHD symptoms and everyday functioning separately from effects on appetite, sleep, pulse, blood pressure and mood.
Children and adolescents need close observation for new suicidal thoughts, unusual behavior and clinical worsening, especially early in treatment or after changes.
Because this is a Schedule III controlled substance, store it securely, never share it and follow disposal instructions for unused capsules.
How do I take it safely?
Simtriyo extended-release capsules contain 140 mg, 210 mg or 280 mg of centanafadine. Take the prescribed capsule in the morning, with or without food, at about the same time each day. Do not cut, crush or chew it.
A capsule may be swallowed whole or opened and all of its contents sprinkled over one tablespoon of applesauce or yogurt, or placed in one tablespoon of orange juice. Consume immediately, follow with water, do not chew the granules and do not save the mixture.
Pediatric dosing is age- and weight-specific. Adults start with the label’s adult dose and may be increased only according to clinical response and tolerability. These label facts are context, not instructions to change a prescription.
MAO inhibitors are contraindicated. Other serotonergic medicines can raise the risk of serotonin syndromeSerotonin syndromeSerotonin syndrome (also called serotonin toxicity) is a potentially life-threatening drug reaction caused by excessive serotonin activity in the nervous system.It can develop soon after starting or increasing a serotonin-affecting medicine, or combining it with another medicine or substance that affects serotonin.Possible signs include agitation or confusion, sweating, fever, diarrhea, shaking, and stiff or twitching muscles.Seek urgent medical help if you suspect serotonin syndrome. Severe symptoms, such as a high fever, seizures, or loss of consciousness, need emergency care.. Centanafadine is a moderate CYP1A2 inhibitor and can increase exposure to medicines processed by that enzyme, so a pharmacist or prescriber should review every prescription, nonprescription medicine and supplement.
Avoid alcohol at the same time as Simtriyo and for at least two hours afterward because alcohol can speed release from the capsule.
If a dose is missed, the label says to take it as soon as remembered but no later than four hours after the usual time. Do not take more than one dose in a day. Ask the prescriber before stopping or changing treatment; urgent safety symptoms require prompt medical advice.
What side effects should I know about?
- Common effects vary by age. They include decreased appetite, rash, nausea, headache, abdominal pain, insomnia, dry mouth or diarrhea.
- Sleepiness, tiredness, dizziness or weight loss can also occur. Pediatric height and weight need follow-up during longer treatment.
Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.
Looking for more detailed information?
The official medicine information lists more side effects, safety advice and product instructions.
- View FDA Prescribing Information (PDF) (opens in a new tab)Simtriyo extended-release capsules
- View official prescribing information (opens in a new tab)Simtriyo extended-release capsules
Which warning signs need help?
- New suicidal thoughts or behavior, severe agitation or a sudden concerning mood change in a child or adolescent requires prompt clinical assessment; imminent danger requires emergency help.
- Chest pain, fainting, a very fast or irregular heartbeat, new psychotic or manic symptoms, or a severe allergic reaction needs urgent medical assessment.
- Fever with agitation, confusion, sweating, muscle stiffness or twitching can be serotonin syndromeSerotonin syndromeSerotonin syndrome (also called serotonin toxicity) is a potentially life-threatening drug reaction caused by excessive serotonin activity in the nervous system.It can develop soon after starting or increasing a serotonin-affecting medicine, or combining it with another medicine or substance that affects serotonin.Possible signs include agitation or confusion, sweating, fever, diarrhea, shaking, and stiff or twitching muscles.Seek urgent medical help if you suspect serotonin syndrome. Severe symptoms, such as a high fever, seizures, or loss of consciousness, need emergency care. and needs emergency care.
What else should I know to stay safe?
- Do not use with an MAO inhibitor or within 14 days after stopping one.
- Do not use after a serious reaction to centanafadine or an ingredient, or in someone with pheochromocytoma or a history of pheochromocytoma.
- Before and during treatment, assess blood pressure, pulse and heart disease. Review bipolar disorder, psychosisPsychosisPsychosis describes symptoms that affect a person’s ability to tell what is real. These can include hallucinations, delusions and disorganized thinking or speech.Psychosis can occur with different mental or physical health conditions, some medicines or substance use. It does not automatically mean schizophrenia. New symptoms need prompt professional assessment., tics or Tourette syndrome, circulation problems and other medicines.
- Assess risk of abuse, misuse and addiction before treatment and during follow-up. Keep capsules secure and never share them.
- Monitor pediatric appetite, weight and growth. Simtriyo is not recommended below age 6 or below 20 kg.
- Simtriyo has an FDA boxed warningFDA boxed warningAn FDA boxed warning is a prominently displayed warning in US prescribing information about especially serious risks, which may include death or serious injury. It is sometimes called a black-box warning.It highlights information that needs particular attention when deciding whether and how to use a medicine. A boxed warning does not mean the medicine is banned or that everyone will experience the harm. Read the medicine-specific warning and discuss it with your prescriber. for suicidal thoughts and behaviors in pediatric patients and for abuse, misuse and addiction. Closely monitor children and adolescents for new suicidal thinking or behavior, and store this Schedule III stimulant securely.
Urgent help and crisis support · Emergency & Crisis Resources (US)
What can help day to day?
- Bring an up-to-date list of prescriptions, nonprescription medicines and supplements to every interaction check.
- The FDA/DailyMed label checked for this article predates DEA scheduling. Centanafadine is now Schedule III under the later rule effective October 30, 2026.
How does it work?
Centanafadine inhibits the transporters that normally take norepinephrine, dopamine and serotonin back into nerve cells. This changes the availability of all three messengers. The FDA label says the exact way this action improves ADHD symptoms is not known.
How was this medicine developed?
The FDA approved Simtriyo on July 24, 2026 as a new molecular entity for ADHD. The approval covered adults and pediatric patients aged 6 years and older who weigh at least 20 kg. The original prescribing information was issued before controlled-substance scheduling, so it displayed schedule-pending placeholders.
On October 30, 2026, DEA issued an interim final rule placing centanafadine, including specified salts and isomers, in Schedule III, effective that day. The rule also opened a comment and hearing period through November 30; that procedure did not delay the effective date.
This sequence is why the current schedule must be read from the later DEA rule, while product indications, administration, warnings and formulation continue to come from FDA-approved labeling.
How do I say the name?
Centanafadine: sen-TAN-uh-fa-deen. Capital letters show the stressed syllable.
Sources and References
Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.
- Simtriyo prescribing information, revised July 2026
- Simtriyo approval history, NDA 218145
- Simtriyo official product labeling
- Placement of centanafadine in Schedule III, effective October 30, 2026
- Centanafadine patient information
- Centanafadine hydrochloride monograph for professionals
- Frequently Asked Questions about Labeling for Prescription Medicines | FDA
- Serotonin syndrome: MedlinePlus Medical Encyclopedia
- Monitoring a person during and after antidepressant switching – NHS SPS - Specialist Pharmacy Service – The first stop for professional medicines advice
- NIMH: Understanding psychosis
Giving medicine safely to children: family guide (PDF, 3 pages)

